REGENSBURG, GERMANY--(Marketwire - June 02, 2009) -
- Daniel Seibert completes GENEART’s management board - Financial expert with over ten years experience in executive positions - New board member possesses broad competences in managing fast growing companies
Regensburg, June 2, 2009 - GENEART AG’s supervisory board appointed Daniel Seibert as member of the management board with immediate effect. He assumes the position of the Chief Financial Officer (CFO) and is responsible for the areas of finances, controlling, procurement and human resources.
Daniel Seibert (40) is a business graduate (“Diplom-Kaufmann”) and possesses many years of experience managing quickly growing companies in dynamic industries. During his most recent engagement, he acted on behalf of financial investors in the renewable energies sector as Chief Financial Officer of Renergys Group AG, Zurich. Previously, he was responsible for business development, restructuring and controlling of the Scout24 Holding GmbH, as commercial managing director. Moreover, Daniel Seibert possesses extensive experience in the areas of capital market oriented evaluation of businesses, mergers and acquisitions as well as the integration of companies, from his position as Head of Investment Analysis & Controlling with T-Online International AG. He started his career at American Express in 1996.
Prof. Dr. Ralf Wagner, CEO of GENEART AG: “I am pleased that with the appointment of Daniel Seibert as CFO, we attracted a highly qualified expert for the position, who perfectly complements our management team. In the long term, we are now superbly positioned to benefit disproportionally high from our market’s growth potential.”
The management team around Prof. Dr. Ralf Wagner (Chief Executive Officer and Chief Scientific Officer) now consists of Dr. Marcus Graf, the company’s co-founder, responsible for production (Chief Operating Officer), Bernd Merkl, as Chief Business Officer in charge of Sales, Marketing and Business Development, and the newly appointed Chief Financial Officer Daniel Seibert.
For further inquiries, please contact: Dr. Karoline Stürmer GENEART AG Josef-Engert-Str. 11 93053 Regensburg Germany Phone: +49-(0)941-942 76-417 Fax: +49-(0)941-942 76-711 ir@geneart.com www.geneart.com Frank Ostermair Better Orange IR & HV AG Haidelweg 48 81241 Munich Germany Phone: +49-(0)89-8896906-10 Fax: +49-(0)89-8896906-66 info@better-orange.de www.better-orange.de
Legal Information
This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.
About GENEART AG:
In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the synthetic biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001:2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. GENEART AG in Regensburg (Germany) and the subsidiaries GENEART Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ more than 190 people. GENEART is listed on the German Stock Exchange.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
